Sight Sciences price target raised to $12 from $7 at UBS

UBS raised the firm’s price target on Sight Sciences (SGHT) to $12 from $7 and keeps a Buy rating on the shares. Medicare Administrative Contractors Novitas and First Coast Service Option established the Medicare fee schedule for TearCare, which represented a critical strategic milestone that increases market access for Sight Sciences’ Dry Eye Solution, and the now-established $1,140 fee offers a clearer line of sight to accelerating TearCare utilization, expanding gross margins, and a potential inflection in revenue growth in 2026, the analyst tells investors in a research note.